Business Context and Reporting Period
This Form 8-K, dated September 24, 2025, reports the effectiveness of the Registration Statement and the consummation of the Initial Public Offering (IPO) by Drugs Made In America Acquisition II Corp., a Cayman Islands-based special purpose acquisition company (SPAC). The IPO closed on September 26, 2025.
Key Financial Metrics
- IPO Proceeds: The Company sold 50,000,000 Units at $10.00 per Unit, generating gross proceeds of $500,000,000.
- Private Placement Proceeds: Simultaneously, the Company sold 1,200,000 Private Units (700,000 to the Sponsor and 500,000 to Cantor Fitzgerald & Co.) at $10.00 per Unit, generating $12,000,000.
- Total Capital Raised: $512,000,000 (excluding underwriting discounts and expenses).
- Trust Account: $500,000,000 of net proceeds from the IPO and Private Placement were deposited into a trust account for public shareholders.
- Over-Allotment Option: Underwriters were granted a 45-day option to purchase up to 7,500,000 additional Units.
- Operating Metrics: The filing does not provide revenue, profit, cash flow, or margin data as the Company is a pre-business combination SPAC.
Material Changes
The primary material change is the transition from a private entity to a public company following the IPO. Key structural changes include:
- Adoption of an Amended and Restated Memorandum and Articles of Association.
- Appointment of Catherine Do, G. Sridhar Prasad, and Myron W. Shulgan to the Board of Directors and various committees.
- Execution of definitive agreements including Underwriting, Rights, Investment Management Trust, and Administrative Services agreements.
Outlook, Risks, and Contingencies
The Company is an emerging growth company seeking an initial business combination. The filing notes the following contingencies and restrictions:
- Lock-Up Periods: Private Units are subject to transfer restrictions until the earlier of six months after the initial business combination or the date the share price exceeds $12.50 for 20 trading days within a 30-day period (for 50% of units).
- Trust Account: Funds are held in trust to be used for the initial business combination or redemption by public shareholders.
- Future Filings: An audited balance sheet reflecting the IPO proceeds is expected to be filed within four business days of the closing.
Investor Verification Checklist
- Verify the final amount of underwriting discounts and commissions deducted from the $500,000,000 gross proceeds.
- Confirm the exact date and content of the audited balance sheet to be filed within four business days of September 26, 2025.
- Review the specific terms of the Investment Management Trust Agreement regarding interest rate assumptions and withdrawal conditions.
- Monitor the exercise of the 45-day over-allotment option by Cantor Fitzgerald & Co.
- Check for any subsequent filings regarding the selection of a target business combination.